REM Sleep Behavior
Axovant is currently conducting a phase 2, multi-center, double-blind, placebo-controlled study evaluating nelotanserin in patients with dementia with Lewy bodies (DLB) experiencing rapid eye movement (REM) sleep behavior disorder (RBD).
The efficacy, safety and tolerability of 80 mg of nelotanserin will be evaluated over a 4-week period in approximately 60 patients with DLB. The primary efficacy evaluation will be a change in the frequency of REM sleep behaviors by the end of 4 weeks. Patients who complete the study will be eligible to receive nelotanserin in an extension study